01/31/12
FDA Approves Kalydeco (VX-770) -- First Drug That Targets the Underlying Cause of Cystic Fibrosis
01/09/12
Vertex Plans Additional Studies of Kalydeco (VX-770) in More CF Patient Groups
12/28/11
Taste of Utah
Volunteers Raise Funds for the Fight Against CF
12/22/11
CF Advocates Advance Research and Preserve Access to Care in 2011
